214 related articles for article (PubMed ID: 33851477)
1. Antibiotics and Imiquimod for Cutaneous T-Cell Lymphoma in Veterans: A Patient Population with Agent Orange Exposure.
Del Guzzo CA; Kojadinovic A; Vinnakota RR; Geskin LJ; Newman JC; Langhoff E; Park YA; Bates SE; Dana AN
Oncologist; 2021 Sep; 26(9):727-e1488. PubMed ID: 33851477
[TBL] [Abstract][Full Text] [Related]
2. Methicillin-resistant Staphylococcus aureus (MRSA) is an important pathogen in erythrodermic cutaneous T-cell lymphoma (CTCL) patients.
Emge DA; Bassett RL; Duvic M; Huen AO
Arch Dermatol Res; 2020 May; 312(4):283-288. PubMed ID: 31776647
[TBL] [Abstract][Full Text] [Related]
3. Management of refractory early-stage cutaneous T-cell lymphoma.
Huber MA; Staib G; Pehamberger H; Scharffetter-Kochanek K
Am J Clin Dermatol; 2006; 7(3):155-69. PubMed ID: 16734503
[TBL] [Abstract][Full Text] [Related]
4. Lifestyle, demographic and Skindex measures associated with cutaneous T-cell lymphoma: a single institution cohort study.
Nguyen M; LeWitt T; Pang Y; Bagnowski K; Espinosa ML; Choi J; Guitart J; Liszewski W; Zhou XA
Arch Dermatol Res; 2023 Mar; 315(2):275-278. PubMed ID: 35668201
[TBL] [Abstract][Full Text] [Related]
5. Second Primary Malignancies in CTCL Patients from 1992 to 2011: A SEER-Based, Population-Based Study Evaluating Time from CTCL Diagnosis, Age, Sex, Stage, and CD30+ Subtype.
Amber KT; Bloom R; Nouri K
Am J Clin Dermatol; 2016 Feb; 17(1):71-7. PubMed ID: 26386881
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous T-Cell Lymphoma Treatment: Case Series of Combination Therapy With Intralesional Injections of 5-Fluorouracil and Topical Imiquimod.
Lindberg MR; DiLorenzo A; DeSimone JA
Cutis; 2023 Jan; 111(1):E19-E25. PubMed ID: 36947768
[TBL] [Abstract][Full Text] [Related]
7. Topical imiquimod as treatment for different kinds of cutaneous lymphoma.
Coors EA; Schuler G; Von Den Driesch P
Eur J Dermatol; 2006; 16(4):391-3. PubMed ID: 16935796
[TBL] [Abstract][Full Text] [Related]
8. Chemical exposures and demographic associations in cutaneous T-cell lymphoma: a large single institution physician validated cohort study.
Ren Z; Chrisman LP; Pang Y; Nguyen M; Hooper MJ; LeWitt TM; Veon FL; Guitart J; Zhou XA
Arch Dermatol Res; 2024 Jan; 316(2):74. PubMed ID: 38236413
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of bexarotene combined with photo(chemo)therapy for cutaneous T-cell lymphoma.
Morita A; Tateishi C; Muramatsu S; Kubo R; Yonezawa E; Kato H; Nishida E; Tsuruta D
J Dermatol; 2020 May; 47(5):443-451. PubMed ID: 32189402
[TBL] [Abstract][Full Text] [Related]
10. Incidence of CTCL in Vietnam veterans.
Meyer KM
Dermatol Nurs; 2002 Feb; 14(1):42, 45, 52. PubMed ID: 11887483
[TBL] [Abstract][Full Text] [Related]
11. Acitretin for the treatment of cutaneous T-cell lymphoma.
Cheeley J; Sahn RE; DeLong LK; Parker SR
J Am Acad Dermatol; 2013 Feb; 68(2):247-54. PubMed ID: 22917895
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive analysis of cutaneous T-cell lymphoma (CTCL) incidence and mortality in Canada reveals changing trends and geographic clustering for this malignancy.
Ghazawi FM; Netchiporouk E; Rahme E; Tsang M; Moreau L; Glassman S; Provost N; Gilbert M; Jean SE; Pehr K; Sasseville D; Litvinov IV
Cancer; 2017 Sep; 123(18):3550-3567. PubMed ID: 28493286
[TBL] [Abstract][Full Text] [Related]
13. Phase I clinical trial of O6-benzylguanine and topical carmustine in the treatment of cutaneous T-cell lymphoma, mycosis fungoides type.
Apisarnthanarax N; Wood GS; Stevens SR; Carlson S; Chan DV; Liu L; Szabo SK; Fu P; Gilliam AC; Gerson SL; Remick SC; Cooper KD
Arch Dermatol; 2012 May; 148(5):613-20. PubMed ID: 22250189
[TBL] [Abstract][Full Text] [Related]
14. Modulation of the skin microbiome in cutaneous T-cell lymphoma delays tumour growth and increases survival in the murine EL4 model.
Dey S; Vieyra-Garcia PA; Joshi AA; Trajanoski S; Wolf P
Front Immunol; 2024; 15():1255859. PubMed ID: 38646524
[TBL] [Abstract][Full Text] [Related]
15. Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002.
Criscione VD; Weinstock MA
Arch Dermatol; 2007 Jul; 143(7):854-9. PubMed ID: 17638728
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous T-cell lymphoma is associated with increased risk of lymphoma, melanoma, lung cancer, and bladder cancer.
Goyal A; O'Leary D; Goyal K; Patel K; Pearson D; Janakiram M
J Am Acad Dermatol; 2021 Dec; 85(6):1418-1428. PubMed ID: 32822803
[TBL] [Abstract][Full Text] [Related]
17. Photopheresis in cutaneous T-cell lymphoma: five-year experience.
Crovetti G; Carabelli A; Berti E; Guizzardi M; Fossati S; De Filippo C; Bertani E
Int J Artif Organs; 2000 Jan; 23(1):55-62. PubMed ID: 12118838
[TBL] [Abstract][Full Text] [Related]
18. New drugs in cutaneous T-cell lymphomas.
Scarisbrick JJ
Curr Opin Oncol; 2016 Sep; 28(5):384-9. PubMed ID: 27390044
[TBL] [Abstract][Full Text] [Related]
19. Characteristics and Outcomes for Hospitalized Patients With Cutaneous T-Cell Lymphoma.
Glinos G; Wei G; Nosewicz J; Abdulla F; Chen PL; Chung C; Kaffenberger BH; Querfeld C; Shinohara MM; Sokol L; Zain J; Kumar A; Seminario-Vidal L
JAMA Dermatol; 2023 Feb; 159(2):192-197. PubMed ID: 36598766
[TBL] [Abstract][Full Text] [Related]
20. Identification of geographic clustering and regions spared by cutaneous T-cell lymphoma in Texas using 2 distinct cancer registries.
Litvinov IV; Tetzlaff MT; Rahme E; Habel Y; Risser DR; Gangar P; Jennings MA; Pehr K; Prieto VG; Sasseville D; Duvic M
Cancer; 2015 Jun; 121(12):1993-2003. PubMed ID: 25728286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
